Read + Share
Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on
monoclonal antibodies on outpatients with Covid-19. PLoS One 2023;18:e0279022.
PMID: 36763607
|
 |
|
Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on
monoclonal antibodies on outpatients with Covid-19. PLoS One 2023;18:e0279022.
PMID: 36763607
|
|
|
|